Clopidogrel before elective percutaneous coronary intervention
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
19789375
DOI
10.1177/0091270009348975
PII: 0091270009348975
Knihovny.cz E-resources
- MeSH
- Angioplasty, Balloon, Coronary * adverse effects MeSH
- Elective Surgical Procedures * MeSH
- Clopidogrel MeSH
- Humans MeSH
- Coronary Artery Disease drug therapy surgery MeSH
- Postoperative Complications etiology prevention & control MeSH
- Preoperative Care * methods MeSH
- Randomized Controlled Trials as Topic methods MeSH
- Ticlopidine analogs & derivatives therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Clopidogrel MeSH
- Ticlopidine MeSH
The introduction of percutaneous coronary intervention (PCI) substantially changed the treatment of patients with coronary artery disease. Stent thrombosis is the most worrisome early complication in patients undergoing PCI. Therefore, antiplatelet therapy forms an integral component of treatment with intracoronary stent implantation. A multitude of randomized and observational studies have helped identify and define the role of clopidogrel in today's PCI patient. Although much is known about its use, a number of questions still remain.
References provided by Crossref.org
